Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

Postoperative Pain Clinical Trial

Official title:

A Phase 2, Randomized, Controlled, Multicenter, Evaluation of the Efficacy and Safety of Locally Administered HTX-011, HTX-002, or HTX-009 for Postoperative Analgesia Following Bunionectomy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02762929
• Other study ID #: HTX-011-C2016-208
• Status: Completed
• Phase: Phase 2
• Start date: May 2016
• Est. completion date: March 2017

Study information

• Verified date: September 2023
• Source: Heron Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 2, Randomized, Controlled, Multicenter, Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

Description:

This study includes multiple formulations for formulation selection of the fixed-combination product and for the factorial design assessment of the contribution of each component. HTX-011A is the second formulation studied (HTX-011-49). HTX-011B is the final formulation studied (HTX-011-56), which was also included in subsequent Phase 2b and Phase 3 studies. For the factorial design assessment, HTX-002, a bupivacaine-only formulation in the same HTX-011 proprietary polymer, and HTX-009, a meloxicam-only formulation in the same HTX-011 proprietary polymer, were evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 430
• Est. completion date: March 2017
• Est. primary completion date: February 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Be male or female 18 years of age or older

2. Female subjects are eligible only if all of the following apply:

1. Not pregnant (female subject of child bearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test before surgery)

2. Not lactating

3. Not planning to become pregnant while participating in the study

4. Be surgically sterile; or be at least two years post-menopausal; or have a monogamous partner who is surgically sterile; or be practicing double-barrier contraception; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than 2 months prior to screening visits and commits to the use of an acceptable form of birth control for the duration of the study and for 30 days from completion of the study

3. Male subjects must be surgically sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study until at least 1 week after the administration of study medication

4. Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair, without collateral procedures, under regional anesthesia

5. Subject has not had a contralateral bunionectomy in the non-study foot in the past 3 months

6. Have the ability and be willing to comply with the study procedures.

7. Must be able to understand study procedures and give informed consent for the conduct for all study procedures, using an IRB approved consent form

Exclusion Criteria:

1. Unwilling to sign informed consent or not willing or able to complete all study procedures

2. Have a contraindication or be allergic to any medication to be used during the trial period

3. Have clinically significant cardiac abnormalities that, in the opinion of the investigator, would pose a health risk to the subject

4. Have American Society of Anesthesiologists (ASA) Physical Status classification system category =4

5. Have clinically significant renal or hepatic abnormalities: for example, AST or ALT > 3x ULN, creatinine > 2x ULN

6. Have another pre-existing painful condition that may confound pain assessments

7. Have another surgery planned within 30 days of procedure

8. Have a known or suspected history of alcohol or drug abuse, or a positive drug screen

9. Currently taking analgesics for a chronically painful condition, or has taken long acting opioids within 3 days of surgery, or taken any opioids within 24 hours of scheduled surgery for this study

10. Subjects with documented sleep apnea or are on home continuous positive airway pressure (CPAP)

11. Subjects who are receiving oxygen therapy at the time of screening

12. Have participated in a clinical trial within 30 days of planned surgery

Related Conditions & MeSH terms

• Bunion
• Bunions
• Pain, Postoperative
• Postoperative Pain

Intervention

Drug:
• HTX-011A
HTX-011A (bupivacaine/meloxicam), via injection.

Biological:
• Saline Placebo
Saline placebo via injection.

Drug:
• HTX-011B
HTX-011B (bupivacaine/meloxicam), via injection or instillation.
• HTX-002
HTX-002, via injection.
• Bupivacaine HCl
Bupivacaine HCI, via injection.
• HTX-009
HTX-009, via injection.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Heron Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Summed Pain Intensity (SPI) Score Over 24 Hours	The SPI is derived by summing the pain intensity score weighted by the scheduled time duration. SPI0-24 will be calculated by summing the Pain intensity (PI) score at the relevant time points weighted by the scheduled time duration since the prior PI assessment as follows: SPI0-24= PI1+PI2+2*PI4+2*PI6+2*PI8+2*PI10+2*PI12+2*PI14+4*PI18+6*PI24. Min = 0 (if PI=0 at every time) and Max = 240 (if PI=10 at every time).	0-24 hours